The Science of Certainty

Rooted in the Gut-Brain-Axis, Gubra enables you to progress your preclinical development for metabolic diseases with more certainty than any other research partner. 


We offer highly specialized CRO services within the
metabolic space. 


We have longstanding experience leading large target and drug
discovery programs with external partners.

We believe 

CSR as usual is not an option

Corporate Responsibility requires more than just big ideas, it requires a firm financial commitment. Gubra is dedicated to donating 10 percent of our pretax profit to social and environmental activities every year.

Upcoming Events

Feb 3-5 EASL Liver Cancer Summit 2022. Meet up with Director and NASH specialist Michael Feigh
Feb 17-19 International Conference in Fatty Liver (ICFL). Meet up with Gubra scientists Malte Hasle Nielsen and Denise Oró
March 1-3 4th Annual CKD Summit. Meet up with principal scientist and kidney expert Mette Viberg Østergaaard
See all events


+ 11 January 2022 The Gubra imaging team came up with the idea of a shared site for virtual neuroscience and exploration of the mouse brain based on expression maps of whole mouse brains donated by laboratories across the world. They call it NeuroPedia. Read more
+ 20 September 2021 Gubra announced the signing of a research collaboration and license agreement with Bayer AG for the development of novel peptide therapeutics to treat cardiorenal diseases. Read more
See all news

Rooted in the Gut-Brain Axis

Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We believe that the next great leap forward in treatment paradigms within obesity, diabetes and related metabolic disorders will be found in the interplay of the gut and the brain.

A better understanding of the gut-brain axis will reveal the aetiology of diabetes, obesity and related metabolic disorders and guide us towards novel future treatments of today’s unmed medical needs.

Latest Gubra webinar

Scientist-to-scientist webinar:

Nephroprotective effects of semaglutide in a preclinical model of hypertensive diabetic kidney disease

In this webinar, Gubra’s experts on preclinical DKD models, Principal Scientists Mette Østergaard and Henrik Björk Hansen, will discuss the effects of semaglutide on renal functional, histological and gene expression markers of advanced DKD in the db/db UNx-ReninAAV mouse.

Play webinar

Release date 27 October. Duration 23 min.

Do you want to be part of a great team aiming high? Join us.

Our ambition is that Gubra is a place where talented people are empowered to put their competencies and passion into play every day. We work as a team to make a difference for people with serious metabolic diseases.